Going concern and financing dependence
Clinical-stage development requires continued external funding before product revenue can support operations
- Scope
- Company-wide
- Materiality
- high
ExpreS2ion Biotech Holding
ExpreS2ion Biotech Holding AB is a Swedish biotechnology holding company built around the ExpreS2 recombinant protein expression platform. Through its operating subsidiary ExpreS2ion Biotechnologies ApS, it develops protein-based vaccine and oncology assets, provides contract research services, and holds interests in collaborative vaccine technology ventures such as AdaptVac.
| % | |
|---|---|
| Proprietary therapeutic programs | 35% Internally developed vaccine and oncology assets advanced through discovery, preclinical and clinical stages. |
| Contract research services | 30% Fee-based protein expression, process development and material supply for external partners. |
| Platform licensing and technology transfer | 15% Licensing of the ExpreS2 platform and transfer of know-how to partners and CDMOs. |
| Collaborative infectious disease programs | 20% Publicly funded and partnered vaccine research in malaria, influenza, Nipah and related areas. |
The company sells primarily to biotechnology and pharmaceutical companies, academic groups, and research consortia that...
- Biotechnology and pharmaceutical companiesprimary
Buy protein expression, process development and research-grade material for difficult constructs and preclinical programs
- Academic and translational research groupssecondary
Use the ExpreS2 platform for discovery-stage expression work and antigen production
- Public research consortia and grant-funded programssecondary
Collaborate on malaria, influenza and Nipah vaccine research using the platform
- Clinical and development partnersprimary
Engage around ES2B-C001 and other assets as programs move toward clinical evaluation
- CDMOs and technology recipientsemerging
Receive transferred processes and platform know-how for downstream manufacturing
The group is headquartered in Sweden but its operating business is primarily based in Denmark through ExpreS2ion...
- •Holding company listed in Sweden on Nasdaq First North Growth Market
- •Operating subsidiary primarily based in Denmark
- •Research collaborations span Europe and global vaccine programs
- •Currency exposure is mainly SEK versus DKK and EUR
- •International development can add USD and GBP exposure
ExpreS2ion’s strategy is to advance ES2B-C001 through early clinical development while preserving ownership of its core...
01
Advance ES2B-C001 in clinical developmentshort-term
The lead oncology asset is the main proprietary value driver and a key source of future partnering optionality
02
Leverage external collaborations for infectious disease programsmedium-term
Partnered programs extend the platform into global health areas while reducing internal capital needs
03
Grow contract research and platform licensingmedium-term
Fee-based work and licensing help monetize the platform beyond a single drug asset
04
Expand and protect intellectual propertylong-term
Patents and know-how support differentiation and future partnering leverage
The company is exposed to clinical development risk, financing risk and the possibility that early-stage programs do...
Clinical development failure
ES2B-C001 and partnered vaccine programs are early-stage and may not produce positive data
- Scope
- ES2B-C001 and collaborative pipeline
- Materiality
- high
Patent and technology protection
The platform’s value depends on proprietary expression methods and related IP
- Scope
- ExpreS2 platform and GlycoX-S2
- Materiality
- high
Currency risk
Operating costs are mainly in DKK/EUR while reporting is in SEK, with potential USD/GBP exposure as development expands
- Scope
- Operating expenses and future clinical spend
- Materiality
- medium
Geopolitical and funding volatility
International collaboration and investor sentiment can be affected by macro and geopolitical uncertainty
- Scope
- Capital access and partner programs
- Materiality
- medium
Going concern assessment
Affects liquidity disclosure, valuation assumptions and investor risk assessment
Revenue recognition for collaborations and services
Can shift revenue between periods
Foreign currency translation
Can create translation and transaction gains or losses
Development and IP-related costs
Affects operating loss and asset base
Equity and share count changes
Impacts per-share metrics and dilution analysis
: 11/08/2026